Alex Bateman is joining the European Bioinformatics Institute as head of protein sequence resources, replacing Rolf Apweiler.
Bateman starts his new job on Nov. 1. He is currently senior investigator at the Wellcome Trust Sanger Institute, where in his 15 years he has led the development of protein and RNA family databases. He has published more than 120 scientific papers and reviews and his work has been cited more than 26,000 times.
Former J&J executive Roy Davis has been appointed to Nanosphere's board.
Davis spent almost 30 years with J&J before retiring on Jan. 1, 2012, and was president of J&J Development and VP of corporate development for all of J&J. Prior to that, Davis was company group chairman and worldwide franchise chairman for diagnostics after running several other J&J businesses.
Sialix has appointed Jeff Behrens as CEO and Julie Hermann as director of business development and operations.
Behrens was previously senior director of business development and operations at Edimer Pharmaceuticals. Before that he was director of strategic alliance at Alnylam.
Hermann was a strategy consultant at Frankel Group and before that held management positions at McKinsey & Company, Amgen, and Cerner.
Quest Diagnostics this week announced the addition of new members to its management team as part of a reorganization, while several senior members are departing.
Everett Cunningham joins Quest as of Oct. 15 as senior vice president, commercial; John Haydon joins the firm on Oct. 22 as SVP, operations; and Jeffrey Shuman joins Quest on Oct. 22 as SVP, chief human resources officer.
Cunningham was most recently regional president of established products, Asia, for Pfizer. Haydon is currently executive VP and global head of operations and business excellence for Philips Electronics. Shuman was most recently SVP, chief human resources and administrative officer for Harris Corp.
Leaving Quest are Richard Mahoney, VP, healthcare information services; Joan Miller, SVP, oncology and neurology services; and David Norgard, VP of human resources. They will leave by the end of the year.
Also, Joseph Benage, VP of insurer and employer services, is leaving in 2013.
Thomas MacMahon is retiring from the board of Laboratory Corporation of America at the end of his current term on May 8, 2013. MacMahon has been a director at the company since 1995, and from 1997 until 2006 he was president and CEO of LabCorp, before retiring. From 2007 to 2009 he served as non-executive chairman of the board.
LabCorp also announced that Peter Neupert has been appointed to the board effective Jan. 1, 2013. He is an operating partner at private equity firm Health Evolution Partners. Prior to joining the company, he was corporate VP of the Microsoft Health Solutions Group from 2005 to 2012 and was president and CEO of drugstore.com from 1998 to 2001. He served on the President's Information Technology Advisory Committee from 2003 to 2005, co-chairing the Health Information Technology subcommittee.
Advion has appointed Vijay Gupta as VP of international business development and support, a position in which he will focus on the firm's expression compact mass spectrometer.
Advion has a multi-channel distribution strategy using distributors, direct sales, and original equipment manufacturer partners, and Gupta will manage and support regional relationships, as well as deal directly with customers in order to broaden Advion's mass spectrometer product lines.
Gupta previously served as head of international sales at Biotage and Biolin.
Genome Canada has appointed Lorne Hepworth the new chair of its board, effective immediately. He replaces Thomas Caskey, who was chair for three years.
Hepworth has been president of CropLife Canada since 1997 and has been a member of the Canadian Agri-Food Research Council, as well as the federal government's Pest Management Advisory Committee and National Biotechnology Advisory Committee. He has been a director of Genome Canada's board since June 2010.
CombiMatrix board member Joseph Limber has resigned, the company said. He also resigned from the audit committee, compensation committee, and nominating and governance committee. He is leaving due to personal reasons.